| pubmed-article:2556108 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:2556108 | lifeskim:mentions | umls-concept:C1267092 | lld:lifeskim |
| pubmed-article:2556108 | lifeskim:mentions | umls-concept:C0040578 | lld:lifeskim |
| pubmed-article:2556108 | lifeskim:mentions | umls-concept:C0021547 | lld:lifeskim |
| pubmed-article:2556108 | lifeskim:mentions | umls-concept:C0031621 | lld:lifeskim |
| pubmed-article:2556108 | lifeskim:mentions | umls-concept:C0243126 | lld:lifeskim |
| pubmed-article:2556108 | lifeskim:mentions | umls-concept:C2246329 | lld:lifeskim |
| pubmed-article:2556108 | lifeskim:mentions | umls-concept:C1880022 | lld:lifeskim |
| pubmed-article:2556108 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:2556108 | pubmed:dateCreated | 1990-1-8 | lld:pubmed |
| pubmed-article:2556108 | pubmed:abstractText | The effects of the muscarinic agonist carbachol, histamine and bradykinin on incorporation of [3H]inositol into the phosphoinositides and the formation of [3H]InsPs were examined in bovine tracheal smooth-muscle (BTSM) slices labelled with [3H]inositol. These agonists result in substantial and dose-related increases in the incorporation of [3H]inositol into the phospholipids. Carbachol and histamine stimulated the incorporation of [3H]inositol into the phospholipids to the same degree, despite histamine being only 35% as effective as carbachol on [3H]InsP accumulation. Histamine and carbachol, at maximal concentrations, were non-additive with respect to both the stimulated incorporation of [3H]inositol and [3H]InsP formation. For carbachol this effect on incorporation was found to occur to a similar extent in PtdInsP and PtdInsP2 as well as PtdIns. The initial effect of carbachol on [3H]inositol incorporation was rapid (maximal by 10 min); however, with prolonged stimulation large secondary declines in PtdInsP and PtdInsP2 labelling were observed, with depletion of the much larger PtdIns pool only evident in the presence of Li+. Lowering buffer [Ca2+] increased the incorporation of [3H]inositol under basal conditions, but did not attenuate the subsequent agonist-stimulated incorporation effect. The large changes in specific radioactivity of the phosphoinositides, and consequently the [3H]InsP products, after carbachol stimulation resulted in the apparent failure of atropine to reverse the [3H]InsP response completely. Labelling muscle slices with [3H]inositol in the presence of carbachol or labelling for longer periods (greater than 6 h) prevented subsequent carbachol-stimulated effects on incorporation without significantly altering the dose-response relationship for carbachol-stimulated [3H]InsP formation and resulted in steady-state labelling conditions confirmed by the ability of atropine to reverse fully the [3H]InsP response to carbachol. This study demonstrates the profound effects of a number of agonists on [3H]inositol incorporation into the phospho- and polyphosphoinositides in BTSM with important consequent changes in the specific radioactivity of these lipids and the resulting [3H]InsP products. In addition, a selective depletion of PtdInsP and PtdInsP2 over PtdIns has been demonstrated with prolonged muscarinic-receptor stimulation. | lld:pubmed |
| pubmed-article:2556108 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2556108 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2556108 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2556108 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2556108 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2556108 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2556108 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2556108 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2556108 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2556108 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2556108 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2556108 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2556108 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2556108 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2556108 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2556108 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2556108 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2556108 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2556108 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2556108 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2556108 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2556108 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2556108 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2556108 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2556108 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2556108 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2556108 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2556108 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2556108 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2556108 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2556108 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2556108 | pubmed:language | eng | lld:pubmed |
| pubmed-article:2556108 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2556108 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:2556108 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2556108 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2556108 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2556108 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2556108 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2556108 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2556108 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2556108 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:2556108 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:2556108 | pubmed:issn | 0264-6021 | lld:pubmed |
| pubmed-article:2556108 | pubmed:author | pubmed-author:NahorskiS RSR | lld:pubmed |
| pubmed-article:2556108 | pubmed:author | pubmed-author:BarneyP LPL | lld:pubmed |
| pubmed-article:2556108 | pubmed:author | pubmed-author:ChilversE RER | lld:pubmed |
| pubmed-article:2556108 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:2556108 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:2556108 | pubmed:volume | 262 | lld:pubmed |
| pubmed-article:2556108 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:2556108 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:2556108 | pubmed:pagination | 739-46 | lld:pubmed |
| pubmed-article:2556108 | pubmed:dateRevised | 2009-11-18 | lld:pubmed |
| pubmed-article:2556108 | pubmed:meshHeading | pubmed-meshheading:2556108-... | lld:pubmed |
| pubmed-article:2556108 | pubmed:meshHeading | pubmed-meshheading:2556108-... | lld:pubmed |
| pubmed-article:2556108 | pubmed:meshHeading | pubmed-meshheading:2556108-... | lld:pubmed |
| pubmed-article:2556108 | pubmed:meshHeading | pubmed-meshheading:2556108-... | lld:pubmed |
| pubmed-article:2556108 | pubmed:meshHeading | pubmed-meshheading:2556108-... | lld:pubmed |
| pubmed-article:2556108 | pubmed:meshHeading | pubmed-meshheading:2556108-... | lld:pubmed |
| pubmed-article:2556108 | pubmed:meshHeading | pubmed-meshheading:2556108-... | lld:pubmed |
| pubmed-article:2556108 | pubmed:meshHeading | pubmed-meshheading:2556108-... | lld:pubmed |
| pubmed-article:2556108 | pubmed:meshHeading | pubmed-meshheading:2556108-... | lld:pubmed |
| pubmed-article:2556108 | pubmed:meshHeading | pubmed-meshheading:2556108-... | lld:pubmed |
| pubmed-article:2556108 | pubmed:meshHeading | pubmed-meshheading:2556108-... | lld:pubmed |
| pubmed-article:2556108 | pubmed:meshHeading | pubmed-meshheading:2556108-... | lld:pubmed |
| pubmed-article:2556108 | pubmed:meshHeading | pubmed-meshheading:2556108-... | lld:pubmed |
| pubmed-article:2556108 | pubmed:meshHeading | pubmed-meshheading:2556108-... | lld:pubmed |
| pubmed-article:2556108 | pubmed:year | 1989 | lld:pubmed |
| pubmed-article:2556108 | pubmed:articleTitle | Characterization of agonist-stimulated incorporation of myo-[3H]inositol into inositol phospholipids and [3H]inositol phosphate formation in tracheal smooth muscle. | lld:pubmed |
| pubmed-article:2556108 | pubmed:affiliation | Department of Pharmacology and Therapeutics, University of Leicester, U.K. | lld:pubmed |
| pubmed-article:2556108 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:2556108 | pubmed:publicationType | In Vitro | lld:pubmed |
| pubmed-article:2556108 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2556108 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2556108 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2556108 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2556108 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2556108 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2556108 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2556108 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2556108 | lld:pubmed |
